Seprafilm

Seprafilm is a bioresorbable adhesion barrier membrane composed of chemically modified sodium hyaluronate (HA) and carboxymethylcellulose (CMC). It is primarily used in abdominal and pelvic laparotomy to reduce the incidence, extent, and severity of postoperative adhesions. The membrane is applied directly to traumatized tissue surfaces where it turns into a hydrated gel, providing a physical barrier for approximately seven days during the critical period of peritoneal repair. It is completely resorbed by the body within 28 days. Originally developed by Genzyme and later part of Sanofi's portfolio, the product line was acquired by Baxter in 2020. While regulated as a medical device in many regions, it is often studied in clinical trials as a pharmacological intervention for adhesion prevention.

Brand names

Seprafilm

Other names

sodium hyaluronate + carboxymethylcellulosehyaluronic acid + carmellose sodium